TICKERNERD
Menu
ACIUACIUHealthcare · Biotechnology

ACIU Stock Forecast: AC Immune SA Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.90
+9.85% on the day

The 4 Wall Street analysts covering AC Immune SA hold a median 12-month price target of $8.55 — +194.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$288.3M
Ticker Nerd rank
34 / 100
Median analyst target
$8.55
Analysts covering
4
Total return, dividends reinvested
1W
+16.5%
1M
+26.1%
YTD
−7.6%
1Y
+38.1%
From 52W high
−27.3%
From 52W low
+42.2%
$2.04
$3.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACIU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AC Immune SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
71
Size
63
Issuance
59
Momentum
49
Revisions
49
Value
41
Growth
37
Accruals
33
Quality
15

Volatility (71): The share price has been relatively steady.

Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACIU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACIU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26ACIUHigh $11.98Median $8.55Low $5.41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5.41Median $8.55High $11.98

The green dot is the last close — the median target sits +194.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026BTIGReiteratesBuy$8.00
5 Aug 2026BTIGReiteratesBuy$8.00
5 Aug 2026BTIGReiteratesBuy—
4 May 2026BTIGReiteratesBuy$8.00
4 May 2026BTIGReiteratesBuy—
16 Mar 2026BTIGReiteratesBuy—
4 Nov 2025BTIGReiteratesBuy—
8 Sept 2025BTIGReiteratesBuy—
1 May 2025HC Wainwright & Co.MaintainsBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright& Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024BTIGInitiatesBuy—
15 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.ReiteratesBuy—
28 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACIU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ACIU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AC Immune SA (ACIU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.1×

Cheaper than 89% of US stocks

Price / sales
16.5×

Cheaper than 10% of US stocks

Price / book
6.6×

Cheaper than 16% of US stocks

EV / EBITDA
−5.1×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
1057.2%

Higher than 99% of US stocks

Earnings growth (YoY)
1057.2%

Higher than 98% of US stocks

Gross margin
—
Operating margin
7.9%

Higher than 60% of US stocks

Net margin
−246.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−78.5%

Higher than 16% of US stocks

Return on assets
−16.0%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACIU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACIUAC Immune SA$288.3M
34
VRXAVERAXA Biotech AG$288.1M
30
ALXOALX Oncology Holdings, Inc.$282.1M
63
FULCFulcrum Therapeutics, Inc.$292.2M
36
CAMPCAMP4 Therapeutics Corp.$281.1M
59
IVVDInvivyd, Inc.$293.6M
19
ELDNEledon Pharmaceuticals, Inc.$280.4M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AC Immune SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACIU news & analysis

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

GlobeNewsWire · 20 Aug 2026positive

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study of ACI-19764, an NLRP3 inhibitor that targets inflammation. The preliminary Phase 1 data were characterized as positive.

Why it matters — This marks early clinical progress for a new pipeline candidate, ACI-19764, that broadens AC Immune's focus into inflammation alongside its existing programmes.

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

AC Immune reported Q2 earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share and improving from a loss of $0.25 per share a year ago. The company also beat revenue estimates for the quarter, according to the headline.

Why it matters — ACIU watchers would care because the company exceeded analyst expectations for the quarter, marking a year-over-year improvement in results.

AC Immune First Half 2026 Financial and Corporate Update

GlobeNewsWire · 5 Aug 2026positive

AC Immune issued its first-half 2026 financial and corporate update, reporting CHF 75.4 million in cash at June 30, 2026, funding into Q4 2027. The company highlighted progress across wholly-owned programs including the Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease, supported by a $4 million grant, the Morphomer Tau program with Lilly, and a $12 million milestone payment from Takeda triggered by initiation of the AD4 cohort in the ABATE trial, with further clinical results anticipated in H2 2026.

Why it matters — ACIU watchers would care because the update confirms near-term clinical catalysts in wholly-owned programs alongside milestone payments and cash visibility extending into Q4 2027.

FAQ

Frequently asked questions about ACIU stock

What is the ACIU stock price forecast for 2026-2027?

The 4 Wall Street analysts covering AC Immune SA have a median 12-month price target of $8.55, with estimates ranging from $5.41 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACIU stock a buy right now?

Of the 4 analysts covering AC Immune SA, 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AC Immune SA 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACIU?

As at 22 Aug 2026, AC Immune SA ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (71 of 100).

Will ACIU stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +194.7% from the last close, and Ticker Nerd's factor model ranks AC Immune SA 34 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACIU stock forecast for 2030?

No analyst covering AC Immune SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACIU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.41 to $12 over the next 12 months.

How has ACIU stock performed over the past year?

AC Immune SA returned +38.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AC Immune SA do?

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company designs, discovers, and develops therapeutic and diagnostic products aimed at prevention, diagnosis, and treatment of these conditions.

What is the latest news on ACIU?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764". AC Immune announced positive interim Phase 1 results from a first-in-human clinical study of ACI-19764, an NLRP3 inhibitor that targets inflammation. The preliminary Phase 1 data were characterized as positive.

Company

About AC Immune SA.

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company designs, discovers, and develops therapeutic and diagnostic products aimed at prevention, diagnosis, and treatment of these conditions. Its proprietary technology platforms, SupraAntigen and Morphomer, enable the creation of antibodies, small molecules, active immunotherapies, and vaccines targeting a broad range of neurodegenerative disorders. AC Immune SA maintains a diversified pipeline featuring multiple clinical-stage candidates, such as ACI-7104, an anti-α-synuclein active immunotherapy for early Parkinson’s disease, ACI-24 and ACI-35 in pharmaceutical collaborations, and small molecule programs including brain-penetrant NLRP3 inhibitors like ACI-19764 and Tau aggregation inhibitors. The company collaborates with leading global pharmaceutical partners, including Janssen Pharmaceuticals, Takeda, Eli Lilly and Co., and others, to advance its programs. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA plays a significant role in addressing the growing challenges of neurodegeneration through innovative therapeutic and diagnostic solutions.

CEO Dr. Andrea Pfeifer Ph.D. · 90 employees · Switzerland · https://www.acimmune.com